AIDPATH is a high-energy EU consortium, dedicated to enable and to augment the next-generation of personalized medicine with gene-engineered immune cells at EU hospitals through the use of AI technology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells modified to express a synthetic chimeric antigen receptor (CAR-T) that are already a revolution-ary novel treatment in hematology and oncology. AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy and to optimize scheduling and resource planning to reduce cost and hospital resource utilization. The consortium members are well-positioned to engage into a productive dialogue with regulators and patients to ensure acceptance and rapid adoption by EU hospitals and industry.